Intercept to Announce Third Quarter 2018 Financial Results on October 31, 2018
Webcast information for this event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept’s website for approximately two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in
|For more information about Intercept, please contact:
|Media inquiries: firstname.lastname@example.org
Source: Intercept Pharmaceuticals, Inc.